Ceredase® (alglucerase injection) is a modified form of the enzyme,
β-glucocerebrosidase (β-Dglucosyl-N-acylsphingosine glucohydrolase,
EC 3.2.1.45). Alglucerase is a monomeric glycoprotein of 497 amino acids with
carbohydrates making up approximately 6% of the molecule (Mr = 59,300
as determined by SDS-PAGE). The unmodified enzyme (β-glucocerebrosidase)
also contains 497 amino acids and contains approximately 12% carbohydrate (Mr
= 67,000). The carbohydrates on the unmodified enzyme consist of N-linked carbohydrate
chains of the complex and high mannose type. Glucocerebrosidase and alglucerase
catalyze the hydrolysis of the glycolipid, glucocerebroside, within the lysosomes
of the reticuloendothelial system.
Alglucerase is prepared by modification of the oligosaccharide chains of human β-glucocerebrosidase. The modification alters the sugar residues at the non-reducing ends of the oligosaccharide chains of the glycoprotein so that they are predominantly terminated with mannose residues which are specifically recognized by carbohydrate receptors on macrophage cells.
Ceredase® (alglucerase injection) is supplied as a clear sterile non-pyrogenic solution
of alglucerase in a citrate buffered solution (53 mM citrate, 143 mM sodium)
containing 1% albumin human USP. The enzyme is supplied in one concentration,
400 units per bottle (80 units/mL) with a fill volume of 5 mL per bottle. An
enzyme unit (U) is defined as the amount of enzyme required to hydrolyze in
one minute one micromole of the synthetic substrate, p-nitrophenyl-β-D-glucopyranoside.
Ceredase® (alglucerase injection) is purified from a large pool of human placental tissue
collected from selected donors. Steps have been introduced into the manufacturing
process to reduce further the risk of viral contamination. However, no procedure
has been shown to be totally effective in removing viral infectivity. (See PRECAUTIONS).
Each lot of product has been tested and found negative for hepatitis B surface
antigen (HBsAg) and for human immunodeficiency virus antigen (HIV-1) and antibody
(HIV-1/2).
Human chorionic gonadotropin (hCG) is a naturally occurring hormone in human
placenta. It is likely the hCG is partially deglycosylated. In vitro
studies have previously demonstrated biological activity of approximately 3
units of hCG activity per unit Ceredase® (alglucerase injection) , as determined by an in
vitrocell based assay. New process steps have since been introduced into
the manufacturing process that significantly reduce the amount of hCG present
in the Ceredase® (alglucerase injection) product. Initial manufacturing data indicate that
the resulting level of hCG in the product is less than 1 µg hCG per mg Ceredase® (alglucerase injection)
protein, as determined by the ELISA assay. These data indicate that the level
of hCG in the product has been reduced about 15 fold as a result of the new
process steps.
What are the possible side effects of alglucerase (Ceredase)?
Some people receiving an alglucerase injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you feel itchy, dizzy, light-headed, or have hives, stomach cramps, pain or tightness in your chest, trouble breathing, or swelling of your face, lips, tongue, or throat.
It may still be possible for you to receive alglucerase after you have had a reaction to it. There are other medications that can be given to you before your alglucerase infusion to help prevent any reaction...
Read All Potential Side Effects and See Pictures of Ceredase »
Last reviewed on RxList: 1/28/2009
This monograph has been modified to include the generic and brand name in many instances.